HemaCare Blog Clinical Trials Begin for CAR-T Immunotherapy for Metastatic Prostate Cancer

Clinical trials have begun with its first round of Metastatic Prostate Cancer patients for immune cell therapy.  Chimeric antigen receptor T cell (CAR-T) therapy uses the body’s own immune cells to target tumor cells. T cells are taken from a patient’s body then genetically modified to target specific protein markers on tumor cells. As research and development of the next generation of cell therapies continue, new efforts are underway to discover new targets for CAR-T cell development.